Priveterra Acquisition Corp II

Priveterra Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2020 and is headquartered in Fort Lauderdale, FL.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tastemaker Acquisition Corporation is a special-purpose acquisition company that engages in capital stock exchange, asset acquisition, stock purchase, reorganization, or other comparable business combinations with one or more enterprises. They collaborate with a company operating in the restaurant, lodging, or adjacent technology and services industries. They plan to merge with a business that is growing, complements management's experience, and can profit from their operational, financial, and capital markets expertise.

AEON Biopharma Inc

Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively.

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Priveterra Acquisition Corp. (Nasdaq: PMGM) (“Priveterra”), a special purpose acquisition company led by Chairman & CEO, Robert Palmisano, along with President, Vikram Malik, and COO and CFO, Oleg Grodnensky, today announced the successful completion of its business combination (the “Business Combination”) with AEON Biopharma, Inc. (“AEON”), a Phase 3 stage-ready biopharmaceutical company developing a proprietary neurotoxin with initial focus on preve.

Priveterra Acquisition Corp. Announces Completion of Business Combination with AEON Biopharma, Inc.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Priveterra Acquisition Corp. (Nasdaq: PMGM) (“Priveterra” and, after the consummation of its pending business combination (the “Business Combination”) and following its name change to AEON Biopharma, Inc., “New AEON”) today announced that NYSE Regulation, on July 13, 2023, authorized New AEON common stock (“New AEON Common Stock”) and New AEON warrants to be listed on NYSE American LLC (“NYSE”) upon the Business Combination with AEON Biopharma, Inc., (“AE.

Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.

Priveterra Acquisition Corp

Priveterra Acquisition said that following its planned business combination with AEON Biopharma the combined company will list on the New York Stock Exchange.

Priveterra Acquisition says it will list on NYSE after AEON combination

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Priveterra Acquisition Corp. (Nasdaq: PMGM) (“Priveterra” and, after the consummation of its pending business combination (the “Business Combination”) and following its name change to AEON Biopharma, Inc., “New AEON”) today announced that, upon the Business Combination with AEON Biopharma, Inc, (“AEON”) following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc., New AEON Common Stock wi.

Priveterra Acquisition Corp. Announces Intention to Transfer to NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.

Financing represents minimum cash required to consummate the business combination and bridge AEON through key episodic migraine data readout Financing represents minimum cash required to consummate the business combination and bridge AEON through key episodic migraine data readout

AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination

IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp. (Nasdaq: PMGM) (“Priveterra”), a special purpose acquisition company, today announced that at least $20 million in additional funding has been committed by existing AEON investors.

AEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million

IRVINE, Calif.--( BUSINESS WIRE )--AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company developing a proprietary botulinum toxin for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp., (Nasdaq: PMGM) (Priveterra), a special purpose acquisition company, today announced the filing of Form S-4 Registration Statement (“S-4”) with the U.S. Securities and Exchange Commission (“SEC”) regarding the recently announced business combination between the two companies.

AEON Biopharma and Priveterra Acquisition Corp. Announce Filing of S-4 Registration Statement for Proposed Business Combination

– Topline data expected to be announced in 2H 2023 –

AEON Biopharma Completes Enrollment in Phase 2 Trial of ABP-450 for Preventive Treatment of Episodic Migraine

IRVINE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications, and Priveterra Acquisition Corp. (Nasdaq: PMGM) (“Priveterra”), a special purpose acquisition company (SPAC), announced that they have entered into a definitive business combination agreement. Upon closing of the proposed transaction, the combined company will operate as AEON Biopharma, Inc. and is expected to list on Nasdaq under the ticker symbol "AEON".

AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology

News for Priveterra Acquisition Corp II Stock (PMGM)